ArticleProteomics2013
Pilot study identifying myosin heavy chain 7, desmin, insulin-like growth factor 7, and annexin A2 as circulating biomarkers of human heart failure.
Article in Proteomics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 68 citations in OpenAlex.
- Right Ventricular Function and a Novel Biomarker After TAVI: Clinical Implications of IGFBP-7.Echocardiography (Mount Kisco, N.Y.) · 2026Article
- Circulating levels of insulin-like growth factor binding protein 7 are associated with risks of chronic diseases and death.npj aging · 2026Article
- IGFBP7 and Heart Failure: From Senescence Biomarker to Therapeutic Target.Current heart failure reports · 2026Review
- Genetic determinants and clinical significance of circulating and tumor-specific levels of insulin-like growth factor binding protein 7 (IGFBP7) in a Swedish breast cancer cohort.Carcinogenesis · 2025Article
- Association between Insulin-Like Growth Factor Binding Protein-7 and Heart Failure.Current medicinal chemistry · 2025Review
- The senescence-inducing factor IGFBP7 and risk of atrial fibrillation: findings from the PREVEND study.NPJ cardiovascular health · 2025Article
- Role of Circulating Biomarkers in Diabetic Cardiomyopathy.Biomedicines · 2024Review
- Characterization of systolic and diastolic function, alongside proteomic profiling, in doxorubicin-induced cardiovascular toxicity in mice.Cardio-oncology (London, England) · 2024Article
- NephroCheck at 10: addressing unmet needs in AKI diagnosis and risk stratification.Clinical kidney journal · 2023Article
- Woven bone formation and mineralization by rat mesenchymal stromal cells imply increased expression of the intermediate filament desmin.Frontiers in endocrinology · 2023Article
- Insulin-like growth factor-binding protein-7 (IGFBP7) links senescence to heart failure.Nature cardiovascular research · 2022Article
- Insulin-like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence.ESC heart failure · 2022Article
- Biomarkers in Acute Heart Failure Syndromes: An Update.Current cardiology reviews · 2022Review
- IGFBP7 and GDF-15, but not P1NP, are associated with cardiac alterations and 10-year outcome in an elderly community-based study.BMC cardiovascular disorders · 2021Article
- Role of some serum biomarkers in the early detection of diabetic cardiomyopathy.Future science OA · 2021Article
- Elevated plasma sRAGE and IGFBP7 in heart failure decrease after heart transplantation in association with haemodynamics.ESC heart failure · 2020Article
- Echocardiographic assessment of insulin-like growth factor binding protein-7 and early identification of acute heart failure.ESC heart failure · 2020Article
- Circulatory factors associated with function and prognosis in patients with severe heart failure.Clinical research in cardiology : official journal of the German Cardiac Society · 2020Article
- Discovery of novel biomarkers for atherosclerotic aortic aneurysm through proteomics-based assessment of disease progression.Scientific reports · 2020Article
- iTRAQ‑based quantitative proteomics analysis of the potential application of secretoneurin gene therapy for cardiac hypertrophy induced by DL‑isoproterenol hydrochloride in mice.International journal of molecular medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
In-depth proteomic analyses offer a systematic way to investigate protein alterations in disease and, as such, can be a powerful tool for the identification of novel biomarkers. Here, we analyzed proteomic data from a transgenic mouse model with cardiac-specific overexpression of activated calcineurin (CnA), which results in severe cardiac hypertrophy. We applied statistically filtering and false discovery rate correction methods to identify 52 proteins that were significantly different in the CnA hearts compared to controls. Subsequent informatic analysis consisted of comparison of these 52 CnA proteins to another proteomic dataset of heart failure, three available independent microarray datasets, and correlation of their expression with the human plasma and urine proteome. Following this filtering strategy, four proteins passed these selection criteria, including myosin heavy chain 7, insulin-like growth factor-binding protein 7, annexin A2, and desmin. We assessed expression levels of these proteins in mouse plasma by immunoblotting, and observed significantly different levels of expression between healthy and failing mice for all four proteins. We verified antibody cross-reactivity by examining human cardiac explant tissue by immunoblotting. Finally, we assessed protein levels in plasma samples obtained from four unaffected and four heart failure patients and demonstrated that all four proteins increased between twofold and 150-fold in heart failure. We conclude that MYH7, IGFBP7, ANXA2, and DESM are all excellent candidate plasma biomarkers of heart failure in mouse and human.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.